Business Description
aTyr Pharma Inc
NAICS : 325414
SIC : 2836
ISIN : US0021202025
Total Employee Number:
58Description
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.69 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.16 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -11.14 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -82.4 | |||||
3-Year EBITDA Growth Rate | 19.6 | |||||
3-Year EPS without NRI Growth Rate | 20.6 | |||||
3-Year FCF Growth Rate | 24.2 | |||||
3-Year Book Growth Rate | -34.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 85.36 | |||||
9-Day RSI | 74.56 | |||||
14-Day RSI | 63.92 | |||||
3-1 Month Momentum % | -42.96 | |||||
6-1 Month Momentum % | -35.11 | |||||
12-1 Month Momentum % | -91.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.78 | |||||
Quick Ratio | 5.78 | |||||
Cash Ratio | 5.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -49.2 | |||||
Shareholder Yield % | -72.32 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -38573.68 | |||||
Net Margin % | -36857.37 | |||||
EBITDA Margin % | -37750.53 | |||||
FCF Margin % | -31168.95 | |||||
OCF Margin % | -31096.32 | |||||
ROE % | -98.48 | |||||
ROA % | -73.24 | |||||
ROIC % | -498.57 | |||||
3-Year ROIIC % | 1279.63 | |||||
ROC (Joel Greenblatt) % | -680.39 | |||||
ROCE % | -89.52 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 344.68 | |||||
PB Ratio | 1.17 | |||||
Price-to-Tangible-Book | 1.17 | |||||
EV-to-EBIT | -0.17 | |||||
EV-to-Forward-EBIT | -0.13 | |||||
EV-to-EBITDA | -0.18 | |||||
EV-to-Forward-EBITDA | -0.13 | |||||
EV-to-Revenue | 66.23 | |||||
EV-to-Forward-Revenue | 1.35 | |||||
EV-to-FCF | -0.21 | |||||
Price-to-GF-Value | 1.5 | |||||
| Price-to-Net-Current-Asset-Value | 1.47 | |||||
| Price-to-Net-Cash | 1.5 | |||||
Earnings Yield (Greenblatt) % | -588.24 | |||||
FCF Yield % | -87.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATYR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
aTyr Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.19 | ||
| EPS (TTM) ($) | -0.73 | ||
| Beta | 0.6549 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.17 | ||
| Volatility % | 101.03 | ||
| 14-Day RSI | 63.92 | ||
| 14-Day ATR ($) | 0.05497 | ||
| 20-Day SMA ($) | 0.510633 | ||
| 12-1 Month Momentum % | -91.15 | ||
| 52-Week Range ($) | 0.395 - 7.2904 | ||
| Shares Outstanding (Mil) | 98.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
aTyr Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
aTyr Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 31 days | ||
| Life Sciences Virtual Investor Forum | 2026-06-25 15:30 | 0.56 (+7.98%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 15:45 | 0.50 (-1.34%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-20 | 0.48 (-3.59%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.56 (+34.30%) | ||
| aTyr Pharma Regulatory and Clinical Update | 2026-05-11 16:30 | 0.95 (+0.67%) | ||
| General meeting for 2026 | 2026-05-11 09:00 | 0.95 (+0.67%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-11 08:00 | 0.94 (+3.52%) | ||
| Annual report for 2025 | 2026-03-05 | 0.96 (+0.47%) |
Show
Entries
aTyr Pharma Inc Frequently Asked Questions
What is aTyr Pharma Inc(ATYR)'s stock price today?
The current price of ATYR is $0.69. The 52 week high of ATYR is $7.29 and 52 week low is $0.40.
When is next earnings date of aTyr Pharma Inc(ATYR)?
The next earnings date of aTyr Pharma Inc(ATYR) is 2026-08-07 Est..
Does aTyr Pharma Inc(ATYR) pay dividends? If so, how much?
aTyr Pharma Inc(ATYR) does not pay dividend.
Guru Commentaries on NAS:ATYR
No articles.
Press Release
Articles on aTyr Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers